What is the recommended treatment approach for a patient co‑infected with HIV and tuberculosis?

Treatment of HIV-TB Co-infection

For patients co-infected with HIV and tuberculosis, initiate a standard 6-month TB regimen with isoniazid, rifampin (or rifabutin if on antiretrovirals), pyrazinamide, and ethambutol, using directly observed therapy, and start antiretroviral therapy within 2 weeks for CD4 <50 cells/mm³ or within 8-12 weeks for higher CD4 counts.

TB Treatment Regimen Selection

For Patients NOT on Antiretroviral Therapy (or Not Requiring Protease Inhibitors/NNRTIs)

• Use the standard 6-month rifampin-based regimen: isoniazid, rifampin, pyrazinamide, and ethambutol (or streptomycin) 1
• Intensive phase (2 months): All four drugs administered either:
  • Daily for 8 weeks, OR
  • Daily for at least 2 weeks, then 2-3 times weekly for 6 weeks 1
• Continuation phase (4 months): Isoniazid and rifampin administered daily or 2-3 times weekly 1

For Patients on Protease Inhibitors or NNRTIs

• Substitute rifabutin for rifampin due to critical drug interactions—rifampin is contraindicated with protease inhibitors and NNRTIs 1
• Intensive phase (2 months): Isoniazid, rifabutin, pyrazinamide, and ethambutol administered:
  • Daily for 8 weeks, OR
  • Daily for at least 2 weeks, then twice weekly for 6 weeks 1
• Continuation phase (4 months): Isoniazid and rifabutin administered daily or twice weekly 1

Critical rifabutin dose adjustments 1:

• With indinavir, nelfinavir, or amprenavir: Reduce rifabutin from 300 mg to 150 mg daily
• With efavirenz: Increase rifabutin to 450 mg daily
• Twice-weekly dosing remains 300 mg regardless of concurrent antiretrovirals
• Increase indinavir dose from 800 mg to 1,200 mg every 8 hours when used with rifabutin 1

For Patients Who Cannot Use Rifamycins

• Use a 9-month streptomycin-based regimen: isoniazid, streptomycin, pyrazinamide, and ethambutol 1
• Intensive phase (2 months): All four drugs administered daily for 8 weeks or daily for 2 weeks then twice weekly for 6 weeks 1
• Continuation phase (7 months): Isoniazid, streptomycin, and pyrazinamide administered 2-3 times weekly 1
• Avoid three-drug regimens (isoniazid, ethambutol, pyrazinamide without rifamycin or aminoglycoside)—if used, treat for minimum 18 months 1

Timing of Antiretroviral Therapy Initiation

CD4 Count <50 cells/mm³

• Start ART within 2 weeks of TB treatment initiation 2, 3, 4
• This timing reduces mortality by 6% (absolute risk reduction) in severely immunosuppressed patients 2

CD4 Count ≥50 cells/mm³

• Defer ART to 8-12 weeks after TB treatment initiation 3, 4
• This approach reduces immune reconstitution inflammatory syndrome (IRIS) risk while maintaining survival benefit 3, 4

Key Considerations for ART Timing

• Earlier ART (≤4 weeks) increases IRIS risk by 6% across all CD4 counts 2
• Earlier ART reduces AIDS-defining events by 2% 2
• Never interrupt ongoing protease inhibitor therapy to use rifampin—this practice is no longer recommended 1
• Wait at least 2 weeks after last rifampin dose before starting protease inhibitors or NNRTIs due to persistent CYP450 induction 1

Essential Supportive Measures

• Pyridoxine (vitamin B6) supplementation is mandatory: 25-50 mg daily or 50-100 mg twice weekly to prevent isoniazid-induced peripheral neuropathy 1
• Directly observed therapy (DOT) should be used for all HIV-TB co-infected patients 1
• Monitor for drug interactions with other HIV medications including azole antifungals, methadone, and hormonal contraceptives 1

Treatment Duration and Monitoring

• Minimum 6 months for rifabutin-based regimens: At least 180 daily doses or equivalent intermittent dosing 1
• Minimum 9 months for streptomycin-based regimens 1
• Drug reactions are more common in HIV-positive patients, including hematologic and hepatic reactions to rifampin, isoniazid, and pyrazinamide 1
• Consider therapeutic drug monitoring for treatment failures or relapses, though not routinely recommended 1

Drug-Resistant TB Considerations

• Isoniazid resistance only: Use rifamycin, pyrazinamide, and ethambutol for 6-9 months or 4 months after culture conversion 1
• Rifampin resistance only: Use 9-month regimen with isoniazid, streptomycin, pyrazinamide, and ethambutol 1
• Multidrug-resistant TB requires expert consultation and individualized regimens 1
• Perform drug susceptibility testing on all TB isolates from HIV-positive patients 5

Common Pitfalls to Avoid

• Do not use rifampin with protease inhibitors or NNRTIs—this causes subtherapeutic antiretroviral levels and treatment failure 1
• Do not delay TB treatment to optimize HIV therapy—TB treatment takes priority 1
• Do not use daily intermittent dosing less than daily for HIV-TB co-infection during intensive phase 1
• Do not forget pyridoxine supplementation—peripheral neuropathy risk is significantly elevated in HIV patients 1